Bayer posts Q3 2023 Group sales Euro 10.34 billion

We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”

Biocon Biologics announces divestment of two non-core branded formulations

Total transaction value of the divestment is Rs. 3,660 million

Evonik launches GMP-quality plant-based squalene

PhytoSquene now available for clinical and commercial use

Indian pharmaceutical companies have become reliable and affordable suppliers of high-quality drugs: MoS Bhagwant Khuba

Lack of technology transfer stands out as a formidable barrier

Supriya Lifescience reports Q2 FY24 PAT higher 42% at Rs. 23.88 Cr

Henkel launches new medical grade wearables device light cure adhesives

The newly developed adhesive is available in two different grades. Loctite WT 3001 and Loctite WT 3003 h

Zydus, Guardant Health to promote Guardant360 genomic tests for cancers in India and Nepal

The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region

The Prostate Cancer Foundation and Bayer announce Bayer – PCF Darolutamide Challenge Awards

In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer

Can-Fite signs agreement with Collaborations Pharmaceuticals to develop anti-cancer drugs using AI

This project will aim to develop a next-generation A3 adenosine receptor drug agonists

Zydus acquires UK based LiqMeds Group

Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026